Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q411787> ?p ?o }
- Q411787 subject Q16075205.
- Q411787 subject Q16816272.
- Q411787 subject Q6814466.
- Q411787 subject Q6900265.
- Q411787 subject Q7145098.
- Q411787 subject Q7237906.
- Q411787 subject Q7931692.
- Q411787 subject Q8256456.
- Q411787 subject Q8390806.
- Q411787 subject Q8614491.
- Q411787 subject Q8790354.
- Q411787 subject Q8802906.
- Q411787 subject Q8805811.
- Q411787 abstract "Miltefosine (INN, trade names Impavido and Miltex) is a broad-spectrum phospholipid antimicrobial drug. Chemically, it is a derivative of lysophospatidylcholine. It was developed in the late 1980s as an experimental cancer treatment by German scientists Hansjörg Eibl and Clemens Unger. Simultaneously, but independently, it was found that the drug could kill Leishmania parasites, and since the mid-1990s, successful clinical trials were conducted. The drug became the first (and still the only prescribed) oral drug in the treatment of leishmaniasis. It is now known to be a broad-spectrum antimicrobial drug, active against pathogenic bacteria and fungi, as well as human trematode Schistosoma mansoni and its vector host, the snail Biomphalaria alexandrina. It can be administered orally and topically.On 19 March 2014, the US Food and Drug Administration approved miltefosine for any form of leishmaniasis, specifically for patients of 12 years of age and older, and became the first approved drug for cutaneous or mucosal leishmaniasis.In 2013, the US Centers for Disease Control and Prevention recommended miltefosine as a monotherapy for granulomatous amoebic encephalitis and primary amoebic meningoencephalitis, two fatal protozoal diseases. Historically, only four survivors have been recorded out of 133 confirmed infections in North America. One American survived the infection in 1978 and one individual from Mexico in 2003. In 2013, two children survived and recovered from primary amoebic meningoencephalitis after treatment with miltefosine.In the target cell, it acts as an protein kinase B (Akt) inhibitor. Therefore, it is also under investigation as a potential therapy against HIV infection.".
- Q411787 atcPrefix "L01".
- Q411787 atcSuffix "XX09".
- Q411787 casNumber "58066-85-6".
- Q411787 chEBI "75283".
- Q411787 fdaUniiCode "53EY29W7EC".
- Q411787 iupacName "2-(hexadecoxy-oxido-phosphoryl)oxyethyl-trimethyl-azanium".
- Q411787 pubchem "3599".
- Q411787 thumbnail Miltefosine.svg?width=300.
- Q411787 wikiPageExternalLink miltefosine.html.
- Q411787 wikiPageExternalLink news.php?Dafra%20Pharma%20R%26D%20has%20been%20awarded%20an%20exclusive%20licence%20from%20the%20Max%20Planck%20Society%20to%20develop%20a%20drug%20against%20leishmaniasis&id=365.
- Q411787 wikiPageExternalLink miltefosine.htm.
- Q411787 wikiPageExternalLink 812862.
- Q411787 wikiPageWikiLink Q10876.
- Q411787 wikiPageWikiLink Q1126189.
- Q411787 wikiPageWikiLink Q1151482.
- Q411787 wikiPageWikiLink Q1152218.
- Q411787 wikiPageWikiLink Q1159908.
- Q411787 wikiPageWikiLink Q12085358.
- Q411787 wikiPageWikiLink Q122224.
- Q411787 wikiPageWikiLink Q127076.
- Q411787 wikiPageWikiLink Q128581.
- Q411787 wikiPageWikiLink Q131260.
- Q411787 wikiPageWikiLink Q131273.
- Q411787 wikiPageWikiLink Q131672.
- Q411787 wikiPageWikiLink Q131924.
- Q411787 wikiPageWikiLink Q132501.
- Q411787 wikiPageWikiLink Q132595.
- Q411787 wikiPageWikiLink Q141124.
- Q411787 wikiPageWikiLink Q150162.
- Q411787 wikiPageWikiLink Q152838.
- Q411787 wikiPageWikiLink Q155.
- Q411787 wikiPageWikiLink Q15787.
- Q411787 wikiPageWikiLink Q16075205.
- Q411787 wikiPageWikiLink Q165399.
- Q411787 wikiPageWikiLink Q16816272.
- Q411787 wikiPageWikiLink Q169480.
- Q411787 wikiPageWikiLink Q170065.
- Q411787 wikiPageWikiLink Q178859.
- Q411787 wikiPageWikiLink Q181876.
- Q411787 wikiPageWikiLink Q184204.
- Q411787 wikiPageWikiLink Q186517.
- Q411787 wikiPageWikiLink Q186889.
- Q411787 wikiPageWikiLink Q186915.
- Q411787 wikiPageWikiLink Q188269.
- Q411787 wikiPageWikiLink Q188874.
- Q411787 wikiPageWikiLink Q1950752.
- Q411787 wikiPageWikiLink Q2046113.
- Q411787 wikiPageWikiLink Q204711.
- Q411787 wikiPageWikiLink Q207547.
- Q411787 wikiPageWikiLink Q221681.
- Q411787 wikiPageWikiLink Q223911.
- Q411787 wikiPageWikiLink Q2303322.
- Q411787 wikiPageWikiLink Q2324689.
- Q411787 wikiPageWikiLink Q238490.
- Q411787 wikiPageWikiLink Q2555060.
- Q411787 wikiPageWikiLink Q2590966.
- Q411787 wikiPageWikiLink Q2757844.
- Q411787 wikiPageWikiLink Q2767140.
- Q411787 wikiPageWikiLink Q29496.
- Q411787 wikiPageWikiLink Q30.
- Q411787 wikiPageWikiLink Q3023727.
- Q411787 wikiPageWikiLink Q306051.
- Q411787 wikiPageWikiLink Q30612.
- Q411787 wikiPageWikiLink Q311383.
- Q411787 wikiPageWikiLink Q331283.
- Q411787 wikiPageWikiLink Q335130.
- Q411787 wikiPageWikiLink Q407972.
- Q411787 wikiPageWikiLink Q410958.
- Q411787 wikiPageWikiLink Q411478.
- Q411787 wikiPageWikiLink Q416077.
- Q411787 wikiPageWikiLink Q423650.
- Q411787 wikiPageWikiLink Q423725.
- Q411787 wikiPageWikiLink Q45959.
- Q411787 wikiPageWikiLink Q4727744.
- Q411787 wikiPageWikiLink Q4915155.
- Q411787 wikiPageWikiLink Q5038170.
- Q411787 wikiPageWikiLink Q513359.
- Q411787 wikiPageWikiLink Q524818.
- Q411787 wikiPageWikiLink Q5596834.
- Q411787 wikiPageWikiLink Q583725.
- Q411787 wikiPageWikiLink Q6060674.
- Q411787 wikiPageWikiLink Q621636.
- Q411787 wikiPageWikiLink Q631521.
- Q411787 wikiPageWikiLink Q649558.
- Q411787 wikiPageWikiLink Q650187.
- Q411787 wikiPageWikiLink Q6814466.